NCT07429227 Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.
| NCT ID | NCT07429227 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Casa di Cura Dott. Pederzoli |
| Condition | Acute Coronary Syndromes (ACS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-03 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2026-03 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.
Eligibility Criteria
Inclusion Criteria: * 1\. Signing of informed consent * 2\. Diagnosis of Acute Coronary Syndrome (ACS) * 3\. Age 30-70 Exclusion Criteria: 1. Use in the three months preceding the signing of the informed consent of: i) Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9) such as Evolocumab and Alirocumab 2. Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.
Frequently Asked Questions
Who can join the NCT07429227 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Acute Coronary Syndromes (ACS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07429227 currently recruiting?
Yes, NCT07429227 is actively recruiting participants. Visit ClinicalTrials.gov or contact Casa di Cura Dott. Pederzoli to inquire about joining.
Where is the NCT07429227 trial being conducted?
This trial is being conducted at Peschiera del Garda, Italy.
Who is sponsoring the NCT07429227 clinical trial?
NCT07429227 is sponsored by Casa di Cura Dott. Pederzoli. The trial plans to enroll 15 participants.